Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Robin E NorrisElizabeth FoxJoel M ReidAndrew RalyaXiaowei W LiuCharles MinardBrenda J WeigelPublished in: Pediatric blood & cancer (2018)
Ontuxizumab administered weekly at 12 mg/kg appears to be well tolerated in children with relapsed or refractory solid tumors. The PK of ontuxizumab does not appear to be significantly different in children compared to adults.